| Abstract | Etanercept is an effective inhibitor of tumor necrosis factor that has shown a beneficial effect in patients with juvenile rheumatoid arthritis (JRA) that did not respond to other disease-modifying drugs. Here we report 3 patients with JRA who were refractory to traditional therapy; 1 with systemic JRA and 2 with polyarticular JRA. They received etanercept 0.4 mg/kg (maximum 25 mg) subcutaneously, twice a week for 3 months. The symptoms of arthritis improved significantly except that the patient with systemic JRA had disease flare-up during etanercept therapy. Two patients had upper respiratory tract infection during etanercept therapy and 1 suffered from seizure attack. The 2 patients with polyarticular JRA had disease flare-up within 2 months after etanercept was discontinued. This is the first report of etanercept treatment in JRA patients in Taiwan. |
| Authors | Jeng-Juh Hung, Jing-Long Huang
(Affiliation: Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung University, Taoyuan, Taiwan.)
|
| Journal | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
(J Microbiol Immunol Infect)
Vol. 38
Issue 6
Pg. 444-6
(Dec 2005)
ISSN: 1684-1182 China |
| PMID | 16341346
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Recombinant Fusion Proteins
- TNFR-Fc fusion protein
- C-Reactive Protein
|
| Topics |
- Antirheumatic Agents
(administration & dosage, adverse effects, therapeutic use)
- Arthritis, Juvenile Rheumatoid
(blood, drug therapy)
- C-Reactive Protein
(metabolism)
- Child
- Female
- Humans
- Immunoglobulin G
(administration & dosage, adverse effects, therapeutic use)
- Male
- Receptors, Tumor Necrosis Factor
(administration & dosage, therapeutic use)
- Recombinant Fusion Proteins
(administration & dosage, adverse effects, therapeutic use)
- Respiratory Tract Infections
(etiology)
- Seizures
(etiology)
|
